Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.36 |
| ▸ | CNR2 | P34972 | 5/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12776101 | 0.88 | RIPK1 (0.61) | RIPK1CNR2SSTR4FFAR4ALOX5AP | |
| SCHEMBL16629597 | 0.86 | P2RX7 (0.43) | P2RX7KDM5AKDM4CKDM5BLRRK2 | |
| SCHEMBL22391509 | 0.85 | RIPK1 (0.55) | RIPK1CNR2SSTR4FFAR4CNR1 | |
| SCHEMBL22391511 | 0.85 | RIPK1 (0.55) | RIPK1CNR2SSTR4FFAR4CNR1 | |
| SCHEMBL22390621 | 0.81 | RIPK1 (0.76) | RIPK1P2RX7KDM5AKDM4CKDM5B | |
| SCHEMBL18014782 | 0.76 | RIPK1 (0.49) | RIPK1SSTR4ALOX5APFEN1 | |
| SCHEMBL12776096 | 0.72 | SLC13A5 (0.48) | RIPK1SSTR4 | |
| SCHEMBL23344679 | 0.71 | SCN9A (0.41) | RIPK1SSTR4 | |
| SCHEMBL22957858 | 0.70 | KDM1A (0.41) | RIPK1CNR2SSTR4FFAR4 | |
| SCHEMBL22957870 | 0.70 | KDM1A (0.41) | RIPK1CNR2SSTR4CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | RIPK1 2370/4885P2RX7 855/4885KDM5A 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.